Core Viewpoint - Microbix Biosystems Inc. and Seegene Mexico are collaborating to enhance the availability of HPV testing and quality assessment products across Mexico, aiming to improve public health efforts in cervical cancer surveillance [1][6]. Group 1: Company Overview - Microbix Biosystems Inc. is a life sciences innovator that manufactures and exports biological products, including laboratory quality assessment products (QAPs) and reference materials, with revenues of C$ 25.4 million in its latest fiscal year [8][9]. - Seegene Mexico, established in 2016, is a subsidiary of Seegene Inc., a leader in multiplex PCR technology, focused on improving diagnostics for infectious diseases, particularly HPV [4][7]. Group 2: Product and Technology - The Allplex and Anyplex HPV 28 Detection assays developed by Seegene Mexico are real-time multiplexing PCR tests that can identify 19 higher-risk and 9 lower-risk HPV genotypes, providing critical infection status and genotype distribution information [3]. - The use of Microbix's QAPs will support the clinical implementation of Seegene's assays, ensuring that clinical labs in Mexico meet international quality standards [5][6]. Group 3: Market Impact - The collaboration is expected to significantly enhance cervical cancer surveillance efforts in Mexico, with a commitment from both companies to support continuous training and quality management systems in clinical laboratories [6][9].